Posts tagged Merck

Bloomberg reported Merck has been eliminating thousands of jobs and trying to boost demand of existing products to overcome the revenue drop from its once-leading drug Singulair, an asthma medication that began facing competition from cheaper copies in August.

Bloomberg reported Merck has been eliminating thousands of jobs and trying to boost demand of existing products to overcome the revenue drop from its once-leading drug Singulair, an asthma medication that began facing competition from cheaper copies in August.

China Diabetes Triples Creating $3.2 Billion Drug Market. Beijing doctor Li Guangwei sees China’s struggle with 90 million diabetes sufferers daily. Among the standing-room-only crowd waiting outside his clinic door are patients with slurred speech, mismatched clothes and aggression.

China Diabetes Triples Creating $3.2 Billion Drug Market. Beijing doctor Li Guangwei sees China’s struggle with 90 million diabetes sufferers daily. Among the standing-room-only crowd waiting outside his clinic door are patients with slurred speech, mismatched clothes and aggression.

Rival hepatitis C drugs from Merck & Co and Vertex Pharmaceuticals are effective in patients also infected with HIV, the virus that causes AIDS, according to data released on Tuesday. The Vertex drug had the more impressive results, the data showed.

Rival hepatitis C drugs from Merck & Co and Vertex Pharmaceuticals are effective in patients also infected with HIV, the virus that causes AIDS, according to data released on Tuesday. The Vertex drug had the more impressive results, the data showed.

Market for hepatitis C drug companies remains in play. Idenix Pharmaceuticals is the latest developer of hepatitis C drugs in the news. In the last two months alone, two other developers of hepatitis C drugs have been scooped up in multibillion-dollar deals, stoking speculation that the 14-year-old Cambridge company may be next in line.
China, the land of opportunity for pharmaceuticals? Merck was the latest pharmaceutical to announce a major investment with the establishment of a new Asian R&D headquarters in Beijing and $1.5 billion to research and development in China over the next five years.

China, the land of opportunity for pharmaceuticals? Merck was the latest pharmaceutical to announce a major investment with the establishment of a new Asian R&D headquarters in Beijing and $1.5 billion to research and development in China over the next five years.

Merck looking for growth, plans to invest $1 billion in Singapore.

Merck looking for growth, plans to invest $1 billion in Singapore.

Among those waiting eagerly for the FDA biosimilars guidelines is Michael Kamarck, president of Merck BioVentures. “We don’t know exactly what the guidelines will say,” Kamarck says. “But we are confident we have a path to move forward and we can succeed.”

Among those waiting eagerly for the FDA biosimilars guidelines is Michael Kamarck, president of Merck BioVentures. “We don’t know exactly what the guidelines will say,” Kamarck says. “But we are confident we have a path to move forward and we can succeed.”

Pfizer’s campaign to promote Lyrica is part of a stepped-up arms race among Western drug makers for a bigger presence in Japan, the world’s second-largest pharmaceuticals market after the U.S., with about $100 billion in yearly sales.

Pfizer’s campaign to promote Lyrica is part of a stepped-up arms race among Western drug makers for a bigger presence in Japan, the world’s second-largest pharmaceuticals market after the U.S., with about $100 billion in yearly sales.

Merck to reduce workforce an additional 12-13% by 2015

The company said it will more aggressively reduce its cost structure so Merck can continue to invest in long term profitable growth opportunities while driving a more efficient operating model. As a result, Merck announced the next phase of its Merger Restructuring Program today. As part of this next phase, the company expects to reduce its workforce, as measured at December 31, 2009, by an additional 12 to 13 percent by the end of 2015. At the same time, Merck said it will continue to hire new employees in strategic growth areas of the business such as emerging markets. Read more here

Merck, Astellas in A-Fib deal

Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc.  today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas. Read more here